Sent to Bruce Patterson henceforth to be known as (BP)
Moving on with the big news today. How can the DMSB look at data if the trial hasnít reached half the patients. Last week were only at 131 of 195 patients needed to get to 50% of critical patients. Did a DMSB always exist or was it recently added as NP implied? Are the interim DMSB looks based on patient numbers treated or based on certain time intervals (like quarterly). I am confused by the sudden change in timelines for the critical covid trial. At one point there was reference to 50 patients triggering a look but I guess that changed too. Based on the India drug results probably the best sign yet that leronlimab will work in covid trials but now you have a safe drug competitor.